FDA reinforces its commitment to fostering personalized medicine by providing a draft guidance to the Congress proposing a framework for LDTs (Laboratory Developed Tests) to establish a better balanced approach for all diagnostics. “We applaud this important step by the FDA to ensure that patients are getting the most accurate, consistent and reliable results from companion diagnostic tests,” said Peer Schatz, CEO of QIAGEN. “The challenge today is not what technology can provide information, but instead how clinically validated information can improve outcomes for patients with cancer and other diseases.” More about the agency’s draft guide: ow.ly/zPNLb
Posted on: Fri, 01 Aug 2014 16:54:21 +0000
Trending Topics
Recently Viewed Topics
© 2015